Novo Nordisk announced the availability of Ozempic (semaglutide) injection 1mg as a single pen containing four 1mg doses for monthly (1 injection/week) maintenance therapy.

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It is also indicated to reduce the risk of major cardiovascular (CV) events (eg, CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with T2DM and established CV disease.

The Company is transitioning away from the currently available 2-pen packaging to the new single monthly pen device, which will contain a larger cartridge to hold four 1mg doses and will include 4 NovoFine Plus needles. A new prescription may be required to receive the new packaging, which will be available beginning in April. 


Continue Reading

According to the Company, the new device will not impact price, coverage, out-of-pocket cost, or the patient savings and support offerings. Existing patients may continue receiving Ozempic injection 1mg in a 2-pen packaging until the single monthly pen becomes readily available.

Pharmacists can access more information about how to dispense the new Ozempic 1mg 1-pen package by downloading the Ozempic Dispensing Quick Reference Guide.  

Ozempic is also available as a single-patient-use pen delivering 0.25mg or 0.5mg per injection.

Reference

Novo Nordisk Transitions to Single Pen for Monthly Supply of Ozempic® (semaglutide) injection 1 mg. [press release]. Novo Nordisk; April 1, 2021. 

This article originally appeared on MPR